CD274 and neoplasm: In this study, 1LM therapy was consistent across all 5 countries, with pembrolizumab monotherapy the most used regimen regardless of tumor histology or PD‐L1 status, and docetaxel monotherapy the most common 2L regimen in all but Germany, which had equal usage of docetaxel + nintedanib.